Clinical Trial Search

Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…

Primary: Number of Subjects With Combined Clinical and Microbiologic Response — 70 Participants

Primary: Post-operative Urinary Tract Infection — 19; 20 Participants

Primary: Number of Participants Who Were Cured — 120; 130 Participants — p=<0.001

Primary: Favorable Clinical Outcomes (FCl) — 170; 132 Participants

Primary: Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success — 62.6; 36.0 percentage of participants

Primary: Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI) — 7; 6 Participants

Primary: Incidence of Urinary Tract Infection — 7; 13 participants

Primary: Number of Participants With Therapeutic Response (TR) (Combined Per Participant Clinical and Microbiological Response) at the Test-of-Cure (TOC) Visit - Micro-ITT NTF-S…

Primary: Number of Participant With Urinary Tract Infection — 12; 13 Participants

Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97

Primary: Urinary Tract Infection — 11; 12 UTI

Primary: UTI Incidence as Described Below, Over the 16 Week Study Period Following Randomization, in the LACTIN-V Treatment Group (Group A) as Compared to the Placebo Group…

Primary: Number of Participants With Overall Success — 36; 17 Participants

Primary: Number of Patients With an Overall Success — 119; 97 Participants

Primary: Recurrent Febrile or Symptomatic Urinary Tract Infection During 2-year Follow-up — 39; 72 participants — p=<0.001

Primary: Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis — 13; 12 Participants

Primary: Urinary Tract Infections — 18; 10 participants

Primary: Number of Participants With Microbiological Response at the Test of Cure (ToC) Visit — 10; 10; 1; 18 Participants

Primary: Participants With Urine Cultures With Bacteriuria (>100,000 Cfu/ml or >=100,000 Cfu/ml) Plus Pyuria (Any WBC) — 26; 32; 21; 27 participants

Primary: Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT)…

Primary: Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) Per Empiric Day — 35023; 25987 Extended-Spectrum Days-of-Therapy

Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as…

Primary: Number of Patients With Adverse Events During and After FMT — 1 Participants

Primary: Number of Participants With Clinical and Microbiological Response — 45; 46; 35 Participants

Primary: Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy — 111; 122 Participants

Primary: Number of Urine Cultures Collected Out of the Total Number Expected to be Collected. — 81; 74; 85; 73 Urine cultures

Primary: Number of Participants With Clinical Cure at Day 7 — 13; 12 participants

Primary: Clinical Cure — 140; 123; 10; 27 participants

Primary: UTI — 15; 14 Participants — p=0.84